Nutrien

Phase A — Understand the business

Lens 1 · Company Overview

Nutrien is the largest crop-inputs company in the world by revenue and the product of a 2018 "merger of equals" between Agrium and Potash Corporation of Saskatchewan (PotashCorp), which began trading on the TSX/NYSE as NTR on 2 January 2018. It is two businesses bolted together:

1. An upstream fertilizer producer — three commodity segments:

• Potash — the crown jewel. Nutrien is the world's largest potash producer, mining from low-cost Saskatchewan operations, with capability raised toward ~15 Mt/yr after the 2022 supply shock. Canada accounts for >30% of global potash production.
• Nitrogen — ammonia/urea/UAN from plants in Georgia, Louisiana, Ohio, Texas and Trinidad. 100% North American / Trinidad gas-fed, a structural cost position.
• Phosphate — the weakest leg; currently under a strategic-alternatives review (reconfigure / partner / sell).

1. A downstream ag-retail distributor — "Nutrien Ag Solutions" (Retail) — the largest agricultural-retail network in the world, selling seed, crop-protection chemicals, fertilizer and agronomic services direct to farmers across North America, South America (Brazil/Australia) through thousands of locations. This is the conglomerate twist: a stable, services-like distribution annuity stapled onto a volatile commodity miner. Retail's adjusted EBITDA was $1.74B in 2025.

Why this structure matters: the bull thesis Nutrien sells the market is that Retail's recurring, proprietary-product margin dampens the brutal cyclicality of fertilizer prices. The bear read (Lens 12/13) is that the market refuses to pay a "compounder" multiple for it and instead applies a holding-company discount — and that Retail is itself cyclical (it just lags).

Contract structure: almost none of the take-or-pay/recurring quality of, say, a midstream or a software name. Fertilizer is sold at spot-linked benchmarks; Retail revenue is seasonal and weather-dependent (Q1 is the seasonal low — Retail did just $108M of adj. EBITDA in Q1 2026 vs a $1.75–1.95B full-year guide, because North American planting hasn't happened yet).

Lens 2 · Supply Chain

Map upstream → Nutrien → end customer, with named stakeholders:

Upstream inputs into Nutrien:

• Natural gas (nitrogen feedstock) — sourced at Henry-Hub-linked North American prices and Trinidad gas. This is the single most important input cost for the Nitrogen segment. North American producers pay a fraction of what Europe pays ($10–17/MMBtu European vs the low-single-digits Henry Hub).
• Potash ore — self-mined in Saskatchewan; Nutrien is vertically integrated upstream here (it is the mine), so its "supplier" is its own orebody. The chokepoint is rail and port (Canpotex, the Saskatchewan potash export consortium of Nutrien + Mosaic, handles offshore logistics).
• Sulphur / phosphate rock — for the Phosphate segment.
• Third-party manufactured product for Retail — Nutrien Ag Solutions resells Bayer, Corteva, BASF, Syngenta, FMC crop-protection and seed alongside its own proprietary brands (Loveland Products / Proven Seed). Here Nutrien is a distributor, dependent on the ag-chem majors as suppliers.

Nutrien itself: mines/manufactures fertilizer + operates the retail network.

Downstream / end customers:

• Offshore potash buyers — India (priced $1229/MT Jan 2026), China ($1120/MT FOB), Brazil, Southeast Asia — via Canpotex.
• North American farmers — direct, both for fertilizer and through Retail.
• Wholesale / dealer channel for nitrogen and phosphate.

Chokepoints & single-source dependencies:

• Canpotex is a genuine chokepoint and a quasi-cartel feature — Nutrien and Mosaic jointly control Canadian seaborne potash logistics, which supports price discipline.
• Rail (CN / CPKC) out of Saskatchewan — a perennial operational risk (winter, strikes).
• Brazil FX — the Retail supply chain in Brazil carries currency risk that has bitten earnings (a $220M FX derivative loss in Q2-2024).

This lens is concrete: the named players are Mosaic (via Canpotex), Bayer/Corteva/BASF/Syngenta/FMC (Retail supply), CN/CPKC (rail), and the offshore buyer geographies India/China/Brazil.

Lens 3 · Competitive Advantages (moats)

The real moats, ranked by durability:

1. Saskatchewan potash cost curve + irreplaceability (strongest). Nutrien sits at the low-cost end of the global potash cost curve on a world-class, multi-decade resource. New potash supply is extraordinarily hard to build — the definitive evidence is BHP's Jansen mine, which just took a $2.3B writedown as Stage-2 costs blew out to $6.9B and first Stage-2 production slipped to ~2031. Jansen's eventual 4.3 Mt is <7% of ~67.6 Mt global capacity. The capital intensity and 7–10 year build time of greenfield potash is itself the moat — it deters entry and is why the incumbents' rents persist.
2. Scale in distribution (Retail). The world's largest ag-retail footprint creates a density/route advantage and a proprietary-product flywheel (Nutrien's own-brand seed/chem carries higher margin than resold third-party product). Switching costs for a farmer are modest but real (agronomic relationship, credit terms, convenience).
3. North American gas-cost position in Nitrogen. Structural, but shared with CF Industries — not proprietary to Nutrien. It is a moat against European and Asian nitrogen, not against domestic peers.
4. Canpotex logistics consortium — collective bargaining power over seaborne potash pricing.

Bargaining power: Strong over offshore potash buyers in tight markets (concentrated supply, hard-to-substitute nutrient); weak in Retail (farmers are price-sensitive and the ag-chem majors hold the branded IP). Over suppliers: as a distributor Nutrien has scale leverage on Bayer/Corteva but those firms own the molecules.

Net: the potash franchise is a genuine wide moat (cost + irreplaceable asset + consortium). Retail is a scale-and-convenience moat, narrower and itself cyclical. Nitrogen is a commodity with a regional cost edge. This is a collection of cyclical franchises, not a compounding moat machine — which is exactly why it trades like a cyclical.

Lens 4 · Segments

No segments.csv exists (research layer empty) — all figures `` from Nutrien's SEC-filed releases. Four reportable segments: Retail (Nutrien Ag Solutions), Potash, Nitrogen, Phosphate.

Adjusted EBITDA by segment (the cleanest cross-period read available):

Company totals (9M, to expose the cycle):

• 9M 2022 (peak): net earnings $6.6B, adj EBITDA $10.1B
• 9M 2024 (trough-ish): net earnings $582M, adj EBITDA $4.3B
• 9M 2025 (recovering): net earnings $1.7B, adj EBITDA $4.8B

Geography: Potash/Nitrogen production is North American; sales are global (heavy offshore potash to India/China/Brazil/SE-Asia). Retail is North America (the bulk) + Brazil + Australia; Brazil is the problem child (impairments + FX). The strategic review explicitly targets Brazil Retail for divestiture-or-fix.

Read: Potash is the earnings swing factor and the quality asset; Retail is the stabiliser; Phosphate + Brazil are the cleanup. EBITDA has roughly halved from the 2022 super-cycle peak and is now grinding back up off the trough on volume records and firmer benchmarks — a mid-cycle recovery, not a new peak.

---

Phase B — Measure performance

Lens 5 · Earnings Result (latest print — Q1 2026)

The latest reported quarter is Q1 2026 (reported ~early May 2026; next print 5 Aug 2026).

• Net earnings: $139M; diluted EPS $0.27.
• Adjusted EBITDA: $1.11B; adjusted EPS $0.51.
• Segment drivers: Potash adj EBITDA $578M on record Q1 volumes of 3.51 Mt; Nitrogen $482M on higher benchmarks + 92% NA ammonia operating rate; Retail just $108M (normal seasonal low — N. American planting falls in Q2).
• Guidance: all FY2026 ranges reaffirmed — Potash volume 14.1–14.8 Mt, Nitrogen 9.2–9.7 Mt, Retail adj EBITDA $1.75–1.95B. Tone: constructive on "tightened global fertilizer fundamentals."
• Balance sheet: adjusted net debt $11.06B, 1.8x adj-net-debt/EBITDA; ~$900M of asset-divestiture gross proceeds since Q4-2024 helped deleverage.
• Capital returned: $409M to shareholders in Q1-26 (dividends + buyback).
• Market reaction: the stock fell ~7% on the print despite record potash volumes and a guidance reaffirmation. The tell: the market wanted more — feedstock-cost commentary, elevated costs, and the seasonally-soft Retail line disappointed, and a reaffirm (not a raise) read as a mild negative against a stock that had already run.

Unusual vs its own history: record Q1 potash volume is genuinely strong; the negative reaction signals expectations had crept up. Nothing alarming on the balance sheet — 1.8x leverage is comfortable mid-cycle for this cohort.

Lens 6 · Earnings Calls (sentiment trend)

No transcripts/ in the research layer; assessment from the Q1-2026 call coverage + 2025 releases.

What management is focused on (recurring, 2025→Q1-26):

• "Structural free cash flow growth" and "capital efficiency" — the dominant new phrase under CEO Ken Seitz.
• Portfolio simplification — the strategic reviews of Phosphate, Trinidad Nitrogen, and Brazil Retail are the centrepiece message.
• Operational reliability / debottlenecking in Nitrogen (the 92% ammonia rate is a deliberately-cited proof point).
• Proprietary-products growth + tuck-in M&A in Retail.

Tone shift over time: from the 2022 "ride the super-cycle, expand capacity" posture → a 2024 defensive/cleanup tone (impairments, Geismar cancellation) → a 2025–26 "self-help / simplify-and-deleverage" tone. The language has moved decisively from growth-and-volume to quality-of-earnings, FCF and capital discipline — a classic late-cycle pivot. They stopped talking up big greenfield ambition (Geismar clean ammonia cancelled) and started talking up divestitures and per-share returns.

Lens 7 · Comps

Peer table — Nutrien vs the global fertilizer cohort. Multiples are `` with date, or n/a. None fabricated.

Read: the striking comp is NTR (~11x fwd P/E) vs CF (~15.65x). CF trades at a premium despite being a single-commodity nitrogen play, because it earns 40%+ EBITDA margins and 25%+ ROE vs Nutrien's blended 15–20% margin / 10–15% ROE (Retail dilutes the consolidated margin). So the market is doing the opposite of paying Nutrien a "stability premium" for its conglomerate structure — it is applying a quality/ROE discount. That is the central valuation debate: is Nutrien's ~11x a cyclical-trough bargain, or a permanent holdco/low-ROE haircut? (Lens 12/13.)

Provenance caveat: I could not source live Mosaic / Yara multiples to a dated outlet, so they are marked n/a rather than guessed. The NTR-vs-CF contrast is the sourced, load-bearing comparison.

Lens 8 · Stock-Price Catalysts (what moves NTR >5%)

The 5-year tape is a commodity-cycle chart, and the >5% moves cluster around:

1. Potash/nitrogen benchmark prices — the dominant driver. The 2022 Russia/Belarus supply shock drove fertilizer prices and NTR earnings to records (9M-22 EBITDA $10.1B); the subsequent 2023–24 price normalization roughly halved earnings and the stock. NTR is, first and foremost, a leveraged bet on the potash and nitrogen price decks.
2. Geopolitical supply events — Belarus sanctions, Russia export complications (together ~40% of global potash supply) move the whole complex.
3. Quarterly prints vs expectations — e.g. the −7% Q1-2026 reaction to a "good but not great / reaffirm-not-raise" quarter.
4. Self-help / portfolio news — strategic-review and divestiture announcements (Phosphate/Trinidad/Brazil) are a newer, idiosyncratic catalyst layer that can de-link NTR from the pure commodity beta if value is crystallised.
5. Ag macro — crop prices (corn/soy), planted-acreage, farmer income — set the demand backdrop for both fertilizer and Retail.

What the pattern reveals: the market reacts to the fertilizer price deck and supply geopolitics far more than to anything company-specific. NTR is priced as a commodity proxy with a self-help option on top. To outperform the index you need a price-deck view plus a value-crystallisation view.

---

Phase C — Judge people & books

Lens 9 · Management

CEO: Ken Seitz (permanent CEO since 2022, after an interim stint; a long-time potash/PotashCorp-lineage operator).

1. Track record: Seitz inherited the post-super-cycle hangover and has executed a credible simplify-and-deleverage program: cancelled the over-ambitious Geismar clean-ammonia project (a good discipline call — wrote off $195M rather than throw good money after bad), took the Brazil Retail impairments ($335M) cleanly, and drove ~$900M of divestitures + a cost-savings program that lifted Retail EBITDA to $1.74B. This is competent stewardship of a cyclical at a low point — capital discipline rather than empire-building.
2. Tenure & skin in the game: Seitz tenure ~4 years. Insider ownership: n/a (no insider-transactions.csv; would verify in the proxy). For a professional-manager-run large-cap, insider ownership is presumptively low — do not assume founder-level alignment.
3. Capital-allocation history: The current regime is shareholder-friendly and disciplined — $2.20/yr dividend (raised ~1%), a 5%-of-shares NCIB buyback, $409M returned in Q1-26 alone, funded partly by divestitures, while holding leverage at a comfortable 1.8x. The cancellation of Geismar and the Phosphate/Trinidad/Brazil pruning show a willingness to shrink to strength — rare and good. The blemish on the franchise's history (pre-Seitz and early) is the 2018 merger itself, whose promised synergies and "compounder" framing the market has never fully rewarded.
4. Red flags: No SEC enforcement (verified, Lens 10). The genuine concern is Brazil Retail — repeated impairments/FX losses suggest the original Brazil expansion was value-destructive, and the market will judge management on whether the divestiture crystallises value or confirms the misstep. No promotional behaviour; comp not flagged as excessive (verify in proxy).
5. Archetype: Professional manager / operator, not founder. For a mature cyclical at mid-cycle, that is appropriate — the job here is disciplined capital allocation and portfolio surgery, which is what Seitz is doing.

Net: a competent, disciplined, shareholder-aligned-by-policy (if not by ownership) management executing the right late-cycle playbook. Not a visionary compounder team — and this business doesn't need one.

Lens 10 · Forensic Red Flags

Forensic lens — every figure ``; no research-layer financials exist to cross-check, which is itself a caveat (this analysis leans on management-reported adjusted figures it could not independently tie to the filings line-by-line).

Income statement:

• "Adjusted EBITDA" vs net earnings gap is large and recurring — Q1-26 adj EBITDA $1.11B vs net earnings $139M; the wedge is D&A (capital-intensive mining), interest on $11B net debt, and add-backs. This is normal for a heavy-asset miner but means adjusted metrics flatter the picture — anchor on net earnings and FCF, not adj EBITDA, when judging cheapness.
• Impairments are a repeat feature: Brazil Retail $335M (Q2-24), Geismar $195M (2024). Recurring "non-cash" impairments are a yellow flag that prior capital allocation over-reached; track whether they keep recurring.

Balance sheet:

• Adjusted net debt $11.06B at 1.8x — manageable mid-cycle, but this is a cyclical: at the trough of the next down-cycle, EBITDA could fall toward ~$4B and that ratio would climb toward ~2.5–3x. Leverage is fine now, a watch-item later.
• Goodwill/intangibles from the 2018 mega-merger + Retail roll-up are large; Brazil impairments show they are not untouchable. Goodwill balance: n/a (verify in 40-F).
• FX exposure (Brazil real) has produced real losses ($220M derivative loss Q2-24) — a genuine, recurring earnings-quality drag, not a one-off.

Cash flow:

• Management's own framing — "structural free cash flow growth" — is a tacit admission that FCF has been lumpy/disappointing and needs fixing. FCF (not adj EBITDA) is the right lens; point-in-time FCF figure: n/a to a clean dated number.

Segment reporting: clean four-segment structure; Retail "proprietary products" margin is a management-defined sub-metric worth watching for mix-flattering.

Regulatory findings (required sub-section):

• SEC Litigation Releases: None — regulatory/regulatory-findings.md confirms 0 LR naming Nutrien, 2021-06-22→2026-06-22 (SEC EDGAR EFTS).
• SEC AAERs: None — 0 AAERs in the same window.
• Non-SEC enforcement (web search per the file's directive — "Nutrien" (FTC OR DOJ OR FDA OR consent decree OR settlement OR fine OR penalty)): no material corporate enforcement action surfaced in the deep-dive searches. Note Nutrien operates mines and chemical plants → routine environmental/safety regulatory exposure (EPA, provincial regulators) is inherent to the sector but nothing rising to a material disclosed enforcement event was found.
• Item 3 / Legal Proceedings (40-F equivalent of 10-K Item 3): could not pull the 40-F legal-proceedings section directly (EDGAR WebFetch 403; file not in research layer) — n/a — not retrieved; flagged as an open item.
• Conclusion: No material regulatory or accounting-fraud findings — verified via SEC EDGAR EFTS (LR + AAER, 0 hits) and web search as of 2026-06-22. The 40-F Item-3 legal-proceedings text remains unverified (open item). The earnings-quality watch-items are recurring impairments and Brazil FX, not fraud.

---

Phase D — Project & stress-test

Lens 11 · Forward Projection (EPS, next three fiscal years)

Build bottom-up from the latest actuals + reaffirmed guidance. All inputs ; outputs with arithmetic. Fiscal year = calendar year; project FY2026 → FY2028.

Anchors:

• Consensus FY2026 EPS ~$6.02, FY2027 EPS ~$5.09. (Note the consensus shape: FY27 < FY26 — the Street models a mild fertilizer-price give-back after 2026's firm benchmarks.)
• Q1-26 adj EPS $0.51 (seasonally weakest quarter); FY26 guide reaffirmed across all segments.
• ~480M shares out (mkt cap $30.2B ÷ $62.86), shrinking via the 5% NCIB.

Base-case logic: I anchor FY26 to the ~$6.02 consensus (guidance reaffirmed, record potash volumes underway). I take FY27 modestly below the $5.09 consensus optimism floor at ~$5.40 — I think the Street is a touch too bearish on FY27 price normalisation given how delayed new supply is (Jansen 2031), but I respect the cyclical down-bias. FY28 recovers to ~$5.75 on continued buyback shrinkage + benchmark re-firming. This is a $5–6 mid-cycle EPS business with a wide cyclical band ($3–7+), not a steady grower.

Brier forecast: NOT logged (--watchlist breadth mode — forecast.ts create is skipped per skill; promotion to a tracked forecast happens only on a committed /thesis pass).

Lens 12 · Bull vs Bear

Bull case. Nutrien is the largest, lowest-cost producer of an irreplaceable nutrient (potash) at a mid-cycle valuation (~11x fwd P/E, ~3.5% yield), with the single most important fact in the entire complex working in its favour: new potash supply cannot be built — BHP's Jansen $2.3B writedown and 2031 slippage is the proof that the incumbent rent is protected for ~5+ more years. Layer on (a) a structural North American nitrogen gas-cost advantage vs gas-starved Europe; (b) a self-help program — divestitures, buybacks, Brazil fix, "structural FCF growth" — that can crystallise value and rerate the holdco discount; (c) a stabilising Retail annuity; (d) Russia/Belarus (~40% of supply) remaining a chronic supply constraint. Earnings surprise lever: any potash-price tightening drops almost entirely to the bottom line (low marginal cost). At ~11x trough-ish earnings with a 3.5% yield and a 5% buyback, you are paid to wait.

Bear case (permanent-impairment-grade risks):

1. It's a price-taker in a normalising commodity. The 2022 super-cycle is over; if Russia/Belarus volumes fully re-enter and Jansen (eventually) plus brownfield expansions add supply, the potash deck rolls over and EPS halves toward the bear ~$3.25 — the 2023-24 round-trip can repeat. This is the core risk: you are buying a cyclical, and the cycle can turn against you regardless of execution.
2. The market structurally won't pay up. The CF comp is damning — CF gets ~15.65x for 40%/25% margins/ROE; Nutrien gets ~11x because Retail drags consolidated ROE to 10-15%. The "conglomerate stability" thesis the 2018 merger sold has never earned a premium — it earns a discount. The bear says this is permanent: Retail isn't a multiple-expander, it's a multiple-anchor.
3. Brazil / Retail capital destruction. Repeated impairments + FX losses suggest the downstream roll-up over-reached; the divestiture could confirm the loss rather than unlock value.

Pre-mortem (it's Dec 2027, thesis broke): Russia and Belarus potash fully normalised, the price deck fell, FY27 EPS printed nearer $4 not $5; the Brazil sale went off at a disappointing price; the buyback didn't move the needle against falling earnings; the stock sat at ~$55 and the "cheap cyclical" turned out to be cheap because earnings were rolling. The error was mistaking a mid-cycle multiple for a trough multiple.

Are multiples too high? No — ~11x fwd P/E is cheap in absolute terms; the risk is the E, not the multiple. The bear isn't "it's expensive," it's "the earnings base is cyclically inflated and the multiple is cheap for a reason (low ROE)."

Contrarian view (what the market refuses to see): the market is treating Nutrien as a pure commodity proxy and ignoring the scarcity-value of the potash franchise in a world where new supply has become near-uninvestable (Jansen's blowup is a bullish signal for incumbents that the market is reading as sector-negative). If Seitz crystallises the holdco discount via divestitures and potash supply stays structurally short, NTR rerates from "cheap cyclical" toward "scarce, cash-returning resource franchise." That optionality is not in an ~11x multiple.

Lens 13 · Devil's Advocate (short-seller)

Dismantling the bull case:

• What structurally breaks the money machine: potash and nitrogen are commodities Nutrien does not price — it harvests a spread that compresses the moment supply normalises. The entire bull case rests on supply staying short (Russia/Belarus constrained, Jansen delayed). Both can reverse: sanctions ease, Belarus reroutes through China, Jansen eventually lands, and brownfield tonnes (including Nutrien's own idled capacity) flood back. The bull thesis is one geopolitical thaw away from breaking.
• Revenue concentration / what shifts: earnings are concentrated in Potash + Nitrogen benchmark prices — a single macro variable. There is no recurring-revenue ballast big enough to matter: Retail is ~$1.75-1.95B of a multi-billion EBITDA base and is itself cyclical (it just lags). The "diversification" is a diversification of cyclicals that mostly correlate.
• Why the moat is weaker than bulls think: the potash moat is real, but the consolidated business is moat-diluted by a low-ROE distribution arm and a value-destructive Brazil chapter. CF earns double Nutrien's ROE without the conglomerate — proof the Retail strategy subtracts, not adds.
• Most dangerous competitor bulls underestimate: not BHP (too slow) — it's the return of low-cost Belarusian/Russian tonnes and Canpotex discipline cracking if Mosaic or new entrants break ranks. And in nitrogen, CF Industries simply does it better (margins, ROE, cleaner story).
• Worst capital-allocation moves: the 2018 merger's never-rewarded synergy story; the Brazil Retail over-expansion (serial impairments); the Geismar clean-ammonia false start ($195M written off). A pattern of over-reach then cleanup.
• What must hold for today's price: potash/nitrogen benchmarks staying firm through 2026-27, Retail hitting guidance, Brazil not getting worse, leverage staying ~1.8x. If growth/price disappoints 20-30%, EPS goes from ~$6 to ~$4 (bear path) and a "cheap" 11x stock re-rates down on lower earnings — a classic cyclical value-trap.
• Single permanently-impairing scenario: a durable return to potash over-supply (Russia/Belarus normalise + global capacity additions) that resets the price deck to the low-end for years — plausibility moderate (not tail; it's literally what happened 2014-2020 before the 2022 shock). That doesn't bankrupt Nutrien (low-cost, 1.8x levered) but it impairs the earnings power the current price assumes.

Short-seller's bottom line: NTR isn't a fraud or a balance-sheet blow-up — it's a high-quality cyclical that the tape keeps mistaking for a compounder. The short is timing, not solvency: you fade it when the potash deck is firm and expectations have crept up (the −7% Q1-26 reaction is a live example), not when it's at cycle-trough.

Lens 14 · Management Questions (ordered by information value)

1. On potash: what is your read on the timing and volume of Belarusian and Russian export normalisation, and at what benchmark price does your low-cost Saskatchewan position stop translating into margin expansion?
2. The market pays CF ~15.65x for 25%+ ROE and pays Nutrien ~11x for 10-15% blended ROE. What is the specific, quantified ROE/FCF path that closes that gap — and by when does Retail stop being a multiple-anchor?
3. On the strategic reviews (Phosphate, Trinidad Nitrogen, Brazil Retail): what are the decision deadlines, and what minimum value/multiple would make a sale preferable to a fix for each?
4. Brazil Retail has produced repeated impairments and FX losses. Was the original Brazil expansion a mistake, and what is the realistic exit value vs invested capital?
5. Define "structural free cash flow growth" precisely: what is the FCF base, the target, the bridge, and the through-cycle FCF you'd underwrite at trough potash prices?
6. At what net-debt/EBITDA ceiling do you prioritise the balance sheet over the buyback — and what does leverage look like in your own trough-price scenario?
7. What is your mid-cycle (not spot) potash and nitrogen price deck, and what normalised EPS does that imply — the number shareholders should actually capitalise?
8. How much idled/curtailable potash capacity do you hold, and under what price/demand conditions do you bring it back — i.e. are you a source of the next over-supply?
9. On capital returns: with the stock at ~11x, why is the buyback only 5% NCIB rather than larger — do you view the equity as materially undervalued, and if so why not lean in harder?
10. Nitrogen depends on cheap North American gas. How do you hedge a structural rise in Henry Hub (LNG-export-driven), and how much of the cost advantage vs Europe is durable?
11. What is the realistic demand growth for potash/nitrogen over the next decade given farmer-economics, soil-nutrient depletion, and biofuel/food-security tailwinds — your secular volume case?
12. Canpotex: how durable is the consortium's pricing discipline, and what is your contingency if a partner or new entrant breaks ranks?
13. What is your M&A appetite post-simplification — are tuck-ins in Retail value-accretive given the ROE drag, or should that capital go to buybacks/debt?
14. Climate/regulatory: what is your exposure to carbon pricing on mining/ammonia, and to potential US-Canada fertilizer tariff frictions?
15. If the potash super-cycle is structurally over, what is the equity story that isn't just "cheap cyclical with a yield"?

---